View Clinical Trial (Medical Research Study)

Randomized, Double-blind, Placebo-controlled, Parallel Group, Multiple Dose, Multicenter Study to Assess Safety & Efficacy of BGP-15 Administered Orally 1 or 2 Times Daily With Metformin & Sulfonylurea or Metformin in T2 Diabetic Patients

---

Conditions:		Diabetes Mellitus
Purpose:		This is a safety and dose finding efficacy study to evaluate the effects of BGP-15 over the dose range of 100 mg/day to 400 mg/day. Doses are applied once or twice a day for 13 weeks as add-on therapy to the combination of metformin and sulfonylurea treatment or metformin alone in patients with Type 2 Diabetes Mellitus.
Study Summary:		This is a randomized, double-blind, placebo-controlled, parallel group, multiple dose, multicenter study with 5 treatment arms and 1 placebo arm. Patients should be treated with both metformin and SU or metformin alone. Patients will be randomized to 100,100 + 100, 200, 200 + 200, and 400 mg/day or placebo, as an add-on to their current treatment. The study consists of 2 periods: - A 14-day screening period for ascertaining the inclusion/exclusion criteria; and, - A 13-week treatment period with different doses of BGP-15 or placebo as an add-on therapy to metformin and SU treatment or metformin treatment alone.
Criteria:		Inclusion criteria Patients meeting all of the following criteria will be eligible for enrollment: 1. Male and female patients with T2DM at time of diagnosis as defined by the American Diabetes Association (ADA) criteria; 2. Age between 30 and 70 years (inclusive); 3. HbA1c ≥7.5% - ≤12.0% at Screening, Visit 1; 4. FPG ≤270 mg/dL (15.0 mmol/L); 5. Body mass index (BMI) >27 and ≤40 kg/m2; 6. Current treatment with either metformin alone or in combination with SU. The dose of the current treatment must be stable for at least 8 weeks prior to randomization. Patients being treated with metformin must be at their optimal or near-optimal dose (≥1500 mg/day ± 500 mg/day for a range of 1000 to 2000 mg/day), and patients being treated with SU must be receiving at least one half of the maximum approved SU dose; 7. Women may be enrolled if all three of the following criteria are met: 1. They have a negative serum pregnancy test at Screening; 2. They are not breast feeding; and, 3. They do not plan to become pregnant during the study AND if one of the following three criteria is met: i. They have had a hysterectomy or tubal ligation at least 6 months prior to signing the informed consent form; ii. They have been postmenopausal for at least 1 year; or, iii. They are of childbearing potential and will practice one of the following methods of birth control throughout the study: injectable or implantable hormonal contraception or intrauterine device; or two of the following methods of birth control throughout the study: oral or patch contraception plus a barrier contraceptive (eg, diaphragm plus spermicide, male or female condom plus spermicide, or vasectomized male partner). Abstinence, partner's use of condoms, and vasectomy are NOT acceptable methods of contraception; 8. Willingness to sign an informed consent document; and, 9. No conditions that hinder participation in the trial, as determined by the Investigator and Sponsor. Exclusion criteria Patients meeting any of the following criteria will be ineligible for enrollment: 1. Treatment with peroxisome proliferator-activated receptor (PPAR) agonists (including fibrates) within the last 3 months; 2. Treatment with dipeptidyl peptidase 4 (DPP-4) inhibitors, acarbose, or incretins within the last 3 months; 3. Chronic use of insulin injections within the last 1 month; 4. Hypoglycemia requiring third party assistance within the last 3 months; 5. Impaired hepatic function measured as alanine aminotransferase (ALAT) >2X the upper reference limit; 6. Impaired renal function measured as serum creatinine >150 umol/L (1.7 mg/dL); 7. Decompensated heart failure (New York Heart Association [NYHA] class III and IV); 8. Unstable angina pectoris or myocardial infarction within the last 12 months; 9. Clinically significant ECG abnormalities at screening including QTc interval (Bazett's) ≥450 msec or AV block >1st degree; 10. Uncontrolled, treated or untreated hypertension (systolic blood pressure [BP] ≥160 mmHg and/or diastolic BP ≥100 mmHg); 11. Any condition that the Investigator and/or Sponsor feel would interfere with trial participation or evaluation of the results eg, drug abuse or serious disease such as acquired immunodeficiency syndrome/human immunodeficiency syndrome (AIDS/HIV) antibodies, Hepatitis B, or Hepatitis C; 12. Pregnancy or breastfeeding, the intention to become pregnant, or judged to be using inadequate contraceptive measures; 13. History of alcohol and/or drug dependence within the last 2 years; 14. Receipt of any investigational drug or medical device within 3 months prior to this trial; 15. Fasting triglycerides >700 mg/dL at screening; or, 16. Diagnosis or treatment of cancer within the past 5 years except for excision of basal cell or squamous cell skin lesions.
NCT ID:		NCT01069965
Primary Contact:		Study Director Peter Damsbo, MD Kinexum LLC, Harper's Ferry, WV, USA Julie B Tobin Phone: +1 714 351 7804 Email: julie.tobin@integrium.com
Backup Contact:		Email: ckremer@msource-cro.com Claudia Kremer Phone: +49 89 21019101 ext. 6735
Location Contact:		Athens, Tennessee 37303 United States There is no listed contact information for this specific location. Site Status: Recruiting

---

---